Drugs / BH002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06231277 | Apr 2022 → Mar 2023 | cancer | Zhuhai Beihai Biotech Co., Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BH002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06231277 ↗ |
| Route | Intravenous | “Subjects will be administered BH002 intravenously.” NCT06231277 ↗ |